Product image of Novorapid Flexpen (Insulin Aspart) supplied by GNH India

Novorapid Flexpen

Active Ingredient:
Insulin Aspart
Origin:
EU

Novorapid Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Flexpen, is a rapid‑acting insulin analog presented as a solution for subcutaneous injection use. It controls blood glucose levels in people with diabetes mellitus. GNH India supplies Novorapid Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Novorapid Flexpen is a rapid‑acting insulin analog that lowers post‑prandial glucose excursions in several diabetes‑related conditions.

  • Type 1 diabetes mellitus: improves mealtime‑related glucose control.
  • Type 2 diabetes mellitus: provides mealtime insulin coverage when oral agents are insufficient.
  • Gestational diabetes mellitus: helps achieve target glucose levels after meals during pregnancy.

How It Works

  • Insulin aspart differs by amino‑acid substitution that reduces hexamer formation, allowing faster absorption after subcutaneous injection. The molecule binds to insulin receptors on muscle and adipose tissue, activating the receptor’s tyrosine‑kinase pathway, which promotes glucose uptake and suppresses hepatic glucose production, thereby rapidly lowering blood glucose.

Side Effects

Adverse reactions to Novorapid Flexpen are reported across a spectrum of frequency.

Common Side Effects

  • Hypoglycaemia: low blood glucose levels, especially if meals are missed or delayed.
  • Injection‑site reactions: redness, swelling, or itching at the injection site.
  • Lipodystrophy: localized changes in fat tissue with repeated injections.
  • Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects

  • Severe hypoglycaemia with neuroglycopenic symptoms.
  • Allergic reactions: urticaria, angio‑edema, or anaphylaxis.
  • Hypersensitivity to any excipient in the pen device.
  • Persistent hyperglycaemia indicating possible insulin resistance.

Precautions & Warnings

When using Novorapid Flexpen, consider the following safety measures.

  • Dose adjustment: modify insulin dose based on carbohydrate intake, activity level, and blood glucose trends.
  • Monitoring: perform regular self‑monitoring of blood glucose to avoid hypoglycaemia.
  • Concomitant medications: assess risk of hypoglycaemia when combined with sulfonylureas or meglitinides.
  • Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision.
  • Renal or hepatic impairment: may require lower doses and closer monitoring.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Novorapid Flexpen may interact with other agents that influence blood glucose levels.

Major Interactions (Avoid)

  • Sulfonylureas or meglitinides: combined use can cause severe hypoglycaemia.
  • Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: can increase insulin requirements.
  • Thiazide diuretics: may raise blood glucose.
  • Alcohol: can cause unpredictable glucose fluctuations.
  • Exercise: intense activity may necessitate dose reduction to prevent hypoglycaemia.

Frequently Asked Questions

Novorapid Flexpen contains insulin aspart, a rapid‑acting insulin analog used to control blood glucose levels after meals in people with diabetes, including type 1, type 2 and gestational diabetes, as part of a comprehensive diabetes management plan.

Insulin aspart is engineered with a single amino‑acid change that speeds its absorption after subcutaneous injection. It binds to insulin receptors, activates cellular pathways that increase glucose uptake and suppress liver glucose output, producing a rapid decline in post‑prandial blood glucose.

The dose of Novorapid Flexpen is individualized; a qualified prescriber determines the amount based on the patient’s carbohydrate intake, blood glucose targets, and overall treatment regimen. Patients should follow the prescribing healthcare professional’s instructions.

Insulin aspart is classified as pregnancy‑category B in many regions and may be used when the clinical benefit outweighs potential risk. It is excreted in small amounts in breast milk, so use during lactation should be discussed with a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Novorapid Flexpen (insulin aspart) has a similar onset and duration to other rapid‑acting analogs such as insulin lispro and insulin glulisine. Differences lie mainly in formulation, device design and manufacturer‑specific stability data; clinical efficacy and safety are comparable when used as directed.

Novorapid Flexpen should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Once in use, the pen can be kept at controlled room temperature (up to 30 °C) for a limited period, as indicated in the product labeling.

The pen delivers a clear insulin solution subcutaneously using a disposable needle. Patients inject into the abdomen, thigh or upper arm, rotating sites with each dose, and follow the manufacturer’s instructions for dose selection, needle attachment, and pen priming.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Prompt recognition and treatment of these events are essential, and patients should be educated on symptom awareness.

Novorapid Flexpen is contraindicated in individuals with a known hypersensitivity to insulin aspart or any pen‑device components. It should also be avoided in patients experiencing severe hypoglycaemia until the underlying cause is addressed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Aspart

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT